It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aquaporin 3 (AQP3), which is mostly expressed in pulmonary epithelial cells, was linked to lung adenocarcinoma (LUAD). However, the underlying functions and mechanisms of AQP3 in the tumor microenvironment (TME) of LUAD have not been elucidated. Single-cell RNA sequencing (scRNA-seq) was used to study the composition, lineage, and functional states of TME-infiltrating immune cells and discover AQP3-expressing subpopulations in five LUAD patients. Then the identifications of its function on TME were examined in vitro and in vivo. AQP3 was associated with TNM stages and lymph node metastasis of LUAD patients. We classified inter- and intra-tumor diversity of LUAD into twelve subpopulations using scRNA-seq analyses. The analysis showed AQP3 was mainly enriched in subpopulations of M2 macrophages. Importantly, mechanistic investigations indicated that AQP3 promoted M2 macrophage polarization by the PPAR-γ/NF-κB axis, which affected tumor growth and migration via modulating IL-6 production. Mixed subcutaneous transplanted tumor mice and Aqp3 knockout mice models were further utilized, and revealed that AQP3 played a critical role in mediating M2 macrophage polarization, modulating glucose metabolism in tumors, and regulating both upstream and downstream pathways. Overall, our study demonstrated that AQP3 could regulate the proliferation, migration, and glycometabolism of tumor cells by modulating M2 macrophages polarization through the PPAR-γ/NF-κB axis and IL-6/IL-6R signaling pathway, providing new insight into the early detection and potential therapeutic target of LUAD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Second Affiliated Hospital of Fujian Medical University, Fujian Provincial Clinical Research Center of Interventional Respirology, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435); The Second Affiliated Hospital of Fujian Medical University, Department of Pulmonary and Critical Care Medicine, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435); Fujian Provincial Key Laboratory of Lung Stem Cells, Ouanzhou, China (GRID:grid.488542.7)
2 The Second Affiliated Hospital of Fujian Medical University, Department of Thoracic Surgery, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435)
3 The Second Affiliated Hospital of Fujian Medical University, Clinical Research Center, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435)
4 UCL Cancer Institute, The Tumor Immunogenomics and Immunosurveillance (TIGI) Lab, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
5 The Second Affiliated Hospital of Fujian Medical University, Fujian Provincial Clinical Research Center of Interventional Respirology, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435); The Second Affiliated Hospital of Fujian Medical University, Clinical Research Center, Quanzhou, China (GRID:grid.488542.7) (ISNI:0000 0004 1758 0435)




